Evidence from clinicopathological studies has displayed that there is an increasing heterogenic expression profile of chromobox 4 (CBX4) in tumor tissular samples with HADA and this alteration statistically modifies the therapeutic efficiency of po-TACE treatment on HCC [19]. Here, CBX4 is linked to hepatocellular carcinoma.